FDA’s Shuren: Staff Overburdened, Review Times Seeing Negative Effects

The head of the US agency’s device center tells Medtech Insight that while he’s proud of his staff for taking on the extra workload due to the pandemic, product review times are slowing because resources are stretched thin.

Shuren_Jeff_1200
CDRH director Jeff Shuren is worried his staff are burning out and as a result reviews are taking longer • Source: Ferdous Al-Faruque

More from Regulation

More from Policy & Regulation